Abstract library

58 results for "Ruszniewski".
#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?
Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
Authors: Lacombe C, De Rycke O, Chen R, Colnot N, ...
#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton
Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Jerome Cros
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Louis de Mestier
#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Philippe Ruszniewski
#3014 The Number of Positive Nodes Accurately Predicts Recurrence after Distal Pancreatectomy for Nonfunctioning Neuroendocrine Neoplasms
Introduction: The most appropriate staging system of metastatic lymph nodes (N) for resected pancreatic neuroendocrine tumors (PanNETs) remains unclear, especially regarding those resected by distal pancreatectomy (DP).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr. Giovanni Guarneri
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#199 Magnetic Resonance Imaging (MRI) v. Endoscopic Ultrasonography (EUS) for the Detection of =10-mm Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (MEN1). A GTE Study
Introduction: In MEN1, the main risk factor of metastases is pancreatic tumor size. We and others recommend limiting surgery to pancreatic tumors >20 mm or growing based on their size measured with EUS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Guillaume Cadiot
#210 Clinical Characteristics of the 5,160 Patients Included in the French Database of the French Endocrine Tumor Group (GTE)
Introduction: An endocrine tumor database was initiated in 2005 by the French endocrine tumor group (GTE). Today, it comprises 5,160 patients, 70% of whom were diagnosed from 2000.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Françoise Borson-Chazot
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond